348 related articles for article (PubMed ID: 25455732)
21. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
22. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
Sridhara R; Mandrekar SJ; Dodd LE
Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
[TBL] [Abstract][Full Text] [Related]
23. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma.
Louvet C; de Gramont A; Tournigand C; Artru P; Maindrault-Goebel F; Krulik M
Cancer; 2001 Jun; 91(11):2033-8. PubMed ID: 11391582
[TBL] [Abstract][Full Text] [Related]
24. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.
Monk BJ; Han E; Josephs-Cowan CA; Pugmire G; Burger RA
Gynecol Oncol; 2006 Aug; 102(2):140-4. PubMed ID: 16790264
[TBL] [Abstract][Full Text] [Related]
25. Optimal assessment of response in ovarian cancer.
Eisenhauer EA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii49-viii51. PubMed ID: 22180400
[TBL] [Abstract][Full Text] [Related]
26. Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.
Colloca G; Venturino A
Med Oncol; 2017 May; 34(5):87. PubMed ID: 28391579
[TBL] [Abstract][Full Text] [Related]
27. "Just Another Statistic".
Machtay M; Glatstein E
Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
[TBL] [Abstract][Full Text] [Related]
28. Treatment goals in ovarian cancer.
Ozols RF
Int J Gynecol Cancer; 2005; 15 Suppl 1():3-11. PubMed ID: 15839952
[TBL] [Abstract][Full Text] [Related]
29. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.
Robinson AG; Booth CM; Eisenhauer EA
Eur J Cancer; 2014 Sep; 50(13):2303-8. PubMed ID: 24974171
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
31. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
32. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
Llovet JM; Montal R; Villanueva A
J Hepatol; 2019 Jun; 70(6):1262-1277. PubMed ID: 30943423
[TBL] [Abstract][Full Text] [Related]
33. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises.
Hey SP; Gyawali B; D'Andrea E; Kanagaraj M; Franklin JM; Kesselheim AS
J Natl Cancer Inst; 2020 Apr; 112(4):335-342. PubMed ID: 31651981
[TBL] [Abstract][Full Text] [Related]
34. Surrogate endpoints for overall survival in lung cancer trials: a review.
Fiteni F; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
[TBL] [Abstract][Full Text] [Related]
35. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
36. Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance.
Minion LE; Coleman RL; Alvarez RD; Herzog TJ
Gynecol Oncol; 2016 Feb; 140(2):193-8. PubMed ID: 26631607
[TBL] [Abstract][Full Text] [Related]
37. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.
Saad ED; Katz A; Buyse M
J Clin Oncol; 2010 Apr; 28(11):1958-62. PubMed ID: 20194852
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
39. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
